The Report “Peptide and Anticoagulant Drugs Market by Type (Hormonal (Insulin, Teriparatide, Calcitonin), Antibioctic (Colistin, Cycloserine), Low molecular weight heparin (Enaxaparin Sodium, Heparin Sodium), Application (Diabetes, Cancer) - India Forecast to 2022” The Indian Heparin Market is expected to reach USD 883.0 Million in 2022 from USD 381.8 Million in 2016 and is expected to register a CAGR of 15.0%.
Factors such as increasing prevalence of chronic diseases, rising aging population, and increasing healthcare expenditure are contributing to the growth of this market.
Don’t miss out on business opportunities in Indian Heparin Market.
Speak to our analyst and gain crucial industry insights that will help your business grow :- https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=77044734
Top-down and bottom-up approaches were used to estimate and validate the size of the Indian peptides and Indian anticoagulant drugs market and to estimate the size of various other dependent submarkets. The overall market size was used in the top-down approach to estimate the sizes of other individual markets (mentioned in the market segmentation by type and application) through percentage splits from secondary and primary research.
The bottom-up approach was also implemented (wherever applicable) for data extracted from secondary research to validate the market segment revenues obtained. Various secondary sources referred to for this research study include publications from government sources such as the Indian Peptide Society (IPS), World Health Organization (WHO), GLOBOCAN, Canadian Institute for Health Information, and India Brand Equity Foundation (IBEF), Indian Council of Medical Research (ICMR), International Osteoporosis Foundation (IOF), Central Drugs Standard Control Organization, Indian Society for Study of Pain (ISSP),
Key players in the Indian peptide drugs market
Key players operating in the Indian peptide drugs market include Abbott Laboratories (U.S.), Sanofi S.A. (France), Eli Lilly and Company (U.S.), Cipla Limited (India), and Biocon Limited (India), Intas Pharmaceuticals Ltd. (India), Sun Pharmaceutical Industries Ltd. (India), Cadila Pharmaceuticals (India), Lupin Limited (India), Emcure Pharmaceuticals Ltd. (India), Novartis International AG (Switzerland), Dr. Reddy’s Laboratories Limited (India), and Alkem Laboratories Limited (India)
Key players in the Indian anticoagulant drugs market
Key players operating in the Indian anticoagulant drugs market include Sanofi (France), Emcure Pharmaceutical Pvt. Ltd. (India), Cipla Ltd. (India), Bharat Serum (India), Pfizer Inc. (US), Abbott Laboratories (US), and Lupin Ltd. (India), Dr. Reddy’s Laboratories (India), Intas Pharmaceuticals Ltd. (India), Samarth Life Sciences (India), Claris Lifesciences Limited (India), Gland Pharma Limited (India), Mylan Pharmaceutical (India), Torrent Pharmaceuticals (India), and Micro Labs Ltd. (India).
To know about the assumptions considered for the study, download the pdf brochure @:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=77044734
Factors such as increasing prevalence of chronic diseases, rising aging population, and increasing healthcare expenditure are contributing to the growth of this market.
Don’t miss out on business opportunities in Indian Heparin Market.
Speak to our analyst and gain crucial industry insights that will help your business grow :- https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=77044734
Top-down and bottom-up approaches were used to estimate and validate the size of the Indian peptides and Indian anticoagulant drugs market and to estimate the size of various other dependent submarkets. The overall market size was used in the top-down approach to estimate the sizes of other individual markets (mentioned in the market segmentation by type and application) through percentage splits from secondary and primary research.
The bottom-up approach was also implemented (wherever applicable) for data extracted from secondary research to validate the market segment revenues obtained. Various secondary sources referred to for this research study include publications from government sources such as the Indian Peptide Society (IPS), World Health Organization (WHO), GLOBOCAN, Canadian Institute for Health Information, and India Brand Equity Foundation (IBEF), Indian Council of Medical Research (ICMR), International Osteoporosis Foundation (IOF), Central Drugs Standard Control Organization, Indian Society for Study of Pain (ISSP),
Key players in the Indian peptide drugs market
Key players operating in the Indian peptide drugs market include Abbott Laboratories (U.S.), Sanofi S.A. (France), Eli Lilly and Company (U.S.), Cipla Limited (India), and Biocon Limited (India), Intas Pharmaceuticals Ltd. (India), Sun Pharmaceutical Industries Ltd. (India), Cadila Pharmaceuticals (India), Lupin Limited (India), Emcure Pharmaceuticals Ltd. (India), Novartis International AG (Switzerland), Dr. Reddy’s Laboratories Limited (India), and Alkem Laboratories Limited (India)
Key players in the Indian anticoagulant drugs market
Key players operating in the Indian anticoagulant drugs market include Sanofi (France), Emcure Pharmaceutical Pvt. Ltd. (India), Cipla Ltd. (India), Bharat Serum (India), Pfizer Inc. (US), Abbott Laboratories (US), and Lupin Ltd. (India), Dr. Reddy’s Laboratories (India), Intas Pharmaceuticals Ltd. (India), Samarth Life Sciences (India), Claris Lifesciences Limited (India), Gland Pharma Limited (India), Mylan Pharmaceutical (India), Torrent Pharmaceuticals (India), and Micro Labs Ltd. (India).
To know about the assumptions considered for the study, download the pdf brochure @:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=77044734
Comments
Post a Comment